Research at Radial

Backed by research.
Driven by care.

Radial clinicians don't just follow the research, they conduct it. From neuromodulation to digital psychiatry, our team actively publishes and participates in clinical trials, ensuring every patient receives care that is grounded in the best available evidence.

Publications

Oct 2024
Mentalizing-Based Therapy
Basic Concepts in Mentalizing-Based Therapy for Emerging Personality Disorders
Laurel L Williams, Carl Fleisher, Owen S Muir, Chris Grimes, Carlene M MacMillan, Robert A Dugger
Personality difficulties in adolescence are often dismissed as a phase — but early intervention matters. This paper introduces core concepts of Mentalizing-Based Therapy for emerging personality disorders, equipping clinicians with a structured approach for younger patients.
Personality Disorders
Mentalizing-Based Therapy
Oct 2024
Deep TMS
Accelerated Dtms Utilization Of H7 Coil For Comorbid Trd: A Case Series
Aslam MacMillan, Carlene MacMillan, Owen Muir
Treatment-resistant depression with comorbidities demands more than standard protocols. This case series examines the use of accelerated dTMS with the H7 coil in complex patients, documenting outcomes that support its use in harder-to-treat presentations.
Depression
Deep TMS
May 2024
Accelerated TMS
Real-world outcomes and predictors of accelerated rTMS treatment response for treatment-resistant depression
Danielle D DeSouza, Erica Nakano, Vivian Hoang, Kim Hoang, David Ling, Owen Muir, Nathan Meng, Noah DeGaetano, Shan H Siddiqi, David Carreon
Who responds to accelerated TMS in the real world — and what predicts success? This analysis of real-world treatment data identifies clinical and demographic factors associated with response, helping clinicians better match patients to this intensive protocol.
Depression
Accelerated TMS
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
Psilocybin is arriving in clinical conversations faster than most primary care clinicians feel prepared for. This primer equips frontline providers with the evidence base, clinical context, and safety considerations needed to counsel patients meaningfully.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Burton J Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
Psychedelic therapy didn't begin in research labs — it has a long, complex history worth understanding. This primer traces the historical foundations of psychedelic medicine, providing primary care clinicians with context for the current therapeutic renaissance.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic therapy: a primer for primary care clinicians—ketamine
Viviana D Evans, Alejandro Arenas, Kenneth Shinozuka, Burton J Tabaac, Bryce D Beutler, Kirsten Cherian, Chelsey Fasano, Owen S Muir
Ketamine is already in primary care — but many clinicians lack a framework for its psychiatric applications. This primer covers mechanism, dosing, evidence, and patient selection, helping frontline providers engage knowledgeably with patients seeking this treatment.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
Bryce D Beutler, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
LSD has re-entered serious clinical research after decades of prohibition. This primer gives primary care clinicians a grounded overview of current evidence, safety data, and therapeutic applications of lysergic acid diethylamide.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—N, N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir
DMT is among the least understood psychedelics entering therapeutic research — and patient questions are outpacing clinical preparation. This primer offers primary care providers a practical evidence review for informed conversations.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine
Kirsten Cherian, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Viviana D Evans, Chelsey Fasano, Owen S Muir
Ibogaine carries both remarkable therapeutic promise and significant safety considerations. This primer helps primary care clinicians understand the evidence, risks, and clinical context for this powerful plant-derived compound.
Depression
Psychedelic Therapy
Mar-Apr 2024
Psychedelic Therapy
Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics
Owen S Muir, Kenneth Shinozuka, Bryce D Beutler, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Burton J Tabaac
Psychedelic therapy isn't just about individual compounds — it requires a framework for evaluating the whole field. This paper maps the strengths, weaknesses, opportunities, and threats facing psychedelic therapeutics as they move toward mainstream medicine.
Depression
Psychedelic Therapy
OCD
Deep TMS
Personality Disorders
Narcissism
Mentalizing-Based Therapy
Personality Disorders
Mentalizing-Based Therapy
Depression
Deep TMS
Depression
Deep TMS
Personality Disorders
Mentalizing-Based Therapy
Personality Disorders
Mentalizing-Based Therapy
Depression
Deep TMS
Movement Disorders
AI / Digital Psychiatry
OCD
Deep TMS
Depression
Deep TMS
Depression
Deep TMS
Depression
Deep TMS
Depression
Ketamine Monitoring
PTSD
Bipolar
TMS
Movement Disorders
AI / Digital Psychiatry
Depression
Accelerated TMS
Movement Disorders
AI / Digital Psychiatry
Depression
Accelerated TMS
OCD
Deep TMS
Depression
Accelerated TMS
Depression
Anxiety
TMS
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Psychedelic Therapy
Depression
Deep TMS
No items found.
Mescaline
Personality Disorders
Mentalizing-Based Therapy
Depression
Accelerated TMS
Depression
Anxiety
Accelerated TMS
Depression
Accelerated TMS
OCD
Deep TMS
Depression
Deep TMS
Depression
Deep TMS
Depression
Accelerated TMS
Depression
Deep TMS
Depression
Accelerated TMS
Depression
Ketamine Therapy
Conditions
Treatments
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Active clinical trials

No items found.

Research team

Dr. Owen Scott Muir

Co-founder & Chief Scientific Officer

MD, DFAACAP

Dual board-certified child, adolescent and adult psychiatrist, and author of the award-winning Frontier Psychiatrists newsletter and podcast

Owen Scott Muir is a dual board-certified psychiatrist pioneering innovative treatments for depression, anxiety, and OCD. When medications and therapy alone aren't enough, he helps patients find hope through evidence-based interventional psychiatry.

Read more

Amna Aslam

Applied Research Specialist

Amna M. Aslam, MBA, MSc, is the Applied Research Specialist at Radial Health and serves as Expert Faculty for the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3). She provides strategic research expertise in clinical outcomes research, post-marketing evidence generation, and health economics, with a focus on translating real-world data into evidence that informs clinical standard practices, healthcare decision-making, and patient access to innovative neuropsychiatric therapies.


Amna’s work spans the design and oversight of real-world evidence and post-marketing studies, clinical outcomes and patient-reported outcomes, and health economics and outcomes research (HEOR) across interventional psychiatry and neurology. She has led numerous investigator-initiated studies, retrospective analyses, prospective observational studies, and scientific publications evaluating innovative neuropsychiatric therapies. Her expertise includes comparative effectiveness research and health economic evaluations, including cost-effectiveness (CEA), cost-utility (CUA), cost-benefit (CBA), budget impact, and quality-adjusted life year (QALY) analyses. She leverages advanced statistical methodologies using SAS, SPSS, and R to generate robust clinical, economic, and patient-centered evidence that informs value-based healthcare decision-making.


Amna earned her Master of Business Administration and Master of Science in Pharmacy Administration with a concentration in Health Economics and Outcomes Research from St. John's University. She previously contributed to research and market access initiatives at Fermata Health and has served as an Community Affairs and Constituent Laison at her local NYS AssemblyMembers Office. Moreover she has served as adjunct professor and graduate research and teaching assistant at St. John's University. Outside of work, Amna enjoys traveling, trying new restaurants, and learning about the intersection of government and healthcare.

Angelique Lucien

Research Coordinator

Angelique Lucien is a Research Coordinator at Radial, where she supports clinical research focused on advancing innovative treatments in psychiatry and brain health. Her work involves coordinating research studies, engaging participants throughout the research process, ensuring regulatory compliance, and contributing to the collection of high-quality clinical data that helps improve treatment outcomes.


With a strong interest in interventional psychiatry, neuroscience, and mental health research, Angelique is passionate about supporting studies that advance our understanding of psychiatric illness and improve treatment options for patients. She is dedicated to helping ensure that research participants have a positive and supportive experience throughout the research process.


Outside of work, Angelique enjoys traveling, spending time with family and friends, trying new restaurants, and staying active. She is driven by a curiosity about the brain and a commitment to improving the lives of individuals affected by mental illness through research and innovation.

Aleah Goodman

Clinical Research Coordinator & Care Navigator

Aleah Goodman is a Clinical Research Coordinator and Patient Care Navigator with research experience in cognitive psychology and behavioral neuroscience. Her work is driven by a deep interest in the relationship between cognition, mental health, and the development of novel psychiatric treatments. She is particularly drawn to understanding how individuals make sense of themselves and perceive their progress over time, and how these experiences can inform increasingly personalized approaches to treatment.

Aleah supports clinical research in interventional psychiatry, including studies on Transcranial Magnetic Stimulation (TMS) and emerging psychiatric medications and technologies. Drawing on her experience as an Interventional Psychiatry Technician and Patient Care Navigator, she focuses on treatment response and patient-reported outcomes across both real-world and research settings with the goal of translating scientific discoveries into meaningful improvements in patient care.

Nicolas Silva

Clinical Research Coordinator & Interventional Psychiatric Technician

Nicolas Silva is a Clinical Research Coordinator and Intervention Psychiatry Technician passionate about advancing mental health research and care.


He holds a degree in Psychological Sciences from the University of Connecticut and is currently pursuing a Master's in Clinical Social Work — driven by a genuine desire to meet people not just in the data, but in the clinic.

His research interests span two areas he finds deeply connected: the role of faith expression in mental health outcomes, and the expanding frontier of interventional psychiatry treatments such as TMS and Spravato. He believes that understanding what gives people meaning — alongside emerging, evidence-based treatments — is essential to advancing compassionate, whole-person care.

Outside of work, Nicolas finds expression through writing poetry and music, playing guitar, and staying active. Creativity and movement are how he stays grounded — and how he brings a little more humanity into everything he does.

Take the first step and talk to a care navigator.

Your care navigator will explain the process, discuss insurance and costs, and connect you with a clinician to explore today’s most advanced mental health treatments.